- CA$7.15bn
- CA$9.91bn
- CA$3.49bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 13.83 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -4.08% | ||
| Dividend Yield (f) | 0.58% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 20.42 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 57.54 | ||
| Price to Sales | 2.05 | ||
| EV to EBITDA | 11.18 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 22.71% | ||
| Return on Equity | 213.47% | ||
| Operating Margin | 22.52% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | 2,940.45 | 3,349.65 | 3,490.83 | 3,396.59 | 3,685.39 | 8.96% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +120.94 | -15.65 | +7.35 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Apotex Health Corp. is a Canada-based global health company. The Company's three business lines comprise conventional generic pharmaceuticals (Conventional Generics); specialty generic pharmaceuticals (Specialty Generics), and Brands & Biosimilars, a business line consisting of biosimilar pharmaceuticals, branded specialty pharmaceuticals, and branded consumer health and wellness products. The Company manages its business across three geographic reportable segments: Canada, the U.S. and International, based on the location of customers. Its conventional generics include small molecule oral solid dose (OSD) (immediate or extended release). Its specialty generics include liquids, inhalers, topicals, powders, injectables, specialty oncology OSDs, and 505(b)(2) repurposed molecules. It covers various therapeutic areas, including ophthalmology, oncology, dermatology, and hematology. Its portfolio consists of over 800 products (over 300 of which are sold across multiple geographic segments).
Directors
- Last Annual
- March 31st, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- September 16th, 2022
- Public Since
- June 10th, 2026
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Toronto Stock Exchange- Shares in Issue
- 228,499,020
- Address
- 150 Signet Drive, TORONTO, M9L 1T9
- Web
- https://www.apotex.com
- Phone
- Auditors
- Ernst & Young LLP
Latest News for APTX
Upcoming Events for APTX
Q2 2027 Apotex Health Corp Earnings Call
Q2 2027 Apotex Health Corp Earnings Release
Similar to APTX
Aurora Cannabis
Toronto Stock Exchange
Auxly Cannabis
Toronto Stock Exchange
Bausch Health Companies
Toronto Stock Exchange
Canopy Growth
Toronto Stock Exchange
Charlotte's Web Holdings
Toronto Stock Exchange
FAQ
As of Today at 01:18 UTC, shares in Apotex Health are trading at CA$31.29. This share price information is delayed by 15 minutes.
Shares in Apotex Health last closed at CA$31.29 and the price had moved by over the past 365 days. In terms of relative price strength the Apotex Health share price has matched the Toronto Stock Exchange 300 Composite Index by over the past year.
The overall consensus recommendation for Apotex Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreApotex Health does not currently pay a dividend.
Apotex Health does not currently pay a dividend.
Apotex Health does not currently pay a dividend.
To buy shares in Apotex Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$31.29, shares in Apotex Health had a market capitalisation of CA$7.15bn.
Here are the trading details for Apotex Health:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: APTX
Based on an overall assessment of its quality, value and momentum Apotex Health is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Apotex Health is CA$41.34. That is 32.12% above the last closing price of CA$31.29.
Analysts covering Apotex Health currently have a consensus Earnings Per Share (EPS) forecast of CA$2.18 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Apotex Health. Over the past six months, its share price has matched the Toronto Stock Exchange 300 Composite Index by .
As of the last closing price of CA$31.29, shares in Apotex Health were trading -7.1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Apotex Health PE ratio based on its reported earnings over the past 12 months is 13.83. The shares last closed at CA$31.29.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Apotex Health's directors